# ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

> **NCT02757326** · PHASE1,PHASE2 · TERMINATED · sponsor: **RedHill Biopharma Limited** · enrollment: 13 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Opaganib

## Key facts

- **NCT ID:** NCT02757326
- **Lead sponsor:** RedHill Biopharma Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-13
- **Primary completion:** 2019-05
- **Final completion:** 2019-05
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Expiration of National Cancer Institute (NCI) funding of the study.
- **Last updated:** 2021-06-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02757326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02757326, "ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02757326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*